전체 프로그램

ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-2 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved2,047 programs
AntibodyLimited DatastaleRochePreclinical

Altuzan (Subconjunctival bevacizumab, Subconjunctival bevacizumab (Altuzan))

Diabetic Macular Edema · Diabetic Macular Edema

#DiabeticMacularEdema#Antibody#Preclinical#monoclonal-antibody#Roche
Trials 1Status Active
CGTLimited DatastaleInstitute of Hematology & Blood…Phase 1

Sup19 CAR-T (Sup19 CAR-T)

B-Acute Lymphoblastic Leukemia; B Acute Lymphoblastic Leukemia/Lymphoma · B-Acute Lymphoblastic Leukemia

#B-AcuteLymphoblasticLeukemia#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
AntibodyLimited DatastaleEli LillyPhase 1

Superselective Intraarterial Cerebral Infusion of Cetuximab (Superselective Intraarterial Cerebral Infusion of Cetuximab)

Glioblastoma Multiforme (GBM); ANAPLASTIC ASTROCYTOMA (AOA) · Glioblastoma Multiforme (GBM)

#GlioblastomaMultiformeGBM#Antibody#Phase1#monoclonal-antibody#ANAPLASTICASTROCYTOMAAOA+1
Trials 1Status Active
AntibodyLimited DatastalePeking Union Medical CollegePreclinical

Surgery combined with secukinumab (Surgery combined with secukinumab)

Hidradenitis Suppurativa (HS); Hidradenitis Suppurativa (Acne Inversa) · Hidradenitis Suppurativa (HS)

#HidradenitisSuppurativaHS#Antibody#Preclinical#monoclonal-antibody#HidradenitisSuppurativaAcneInver+1
Trials 1Status Recruiting
AntibodyLimited DatastaleBeijing Chest HospitalPhase 2

Surufatinib Durvalizumab EP/EC (Surufatinib Durvalizumab EP/EC)

Extensive-stage Small-cell Lung Cancer · Extensive-stage Small-cell Lung Cancer

#Extensive-stageSmall-cellLungCan#Antibody#Phase2#monoclonal-antibody#Beijing
Trials 1Status Active
AntibodyLimited DatastaleSanofiPreclinical

Systemic dupilumab (Systemic dupilumab)

Dermatitis, Atopic · Dermatitis, Atopic

#DermatitisAtopic#Antibody#Preclinical#monoclonal-antibody#Dermatitis+2
Trials 1Status Active
AntibodyLimited DatastaleUMC UtrechtPhase 2

FTD-TPI and bevacizumab (Systemic treatment, Systemic treatment (FTD-TPI and bevacizumab))

Metastatic Colorectal Cancer · Metastatic Colorectal Cancer

#MetastaticColorectalCancer#Antibody#Phase2#monoclonal-antibody#UMC
Trials 1Status Recruiting
AntibodyLimited DatastaleAgendiaApproved

trastuzumab (Herceptin, T + trastuzumab followed by CEF + trastuzumab)

Breast Cancer · Breast Cancer

#BreastCancer#Antibody#Approved#monoclonal-antibody#Agendia
Trials 1Status Active
CGTLimited DatastalePersonGen BioTherapeutics (Suzh…Phase 1

T cell injection targeting B7-H3 chimeric antigen receptor (T cell injection targeting B7-H3 chimeric antigen receptor)

B7-H3-positive Relapsed/ Refractory Neuroblastoma · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastalePersonGen BioTherapeutics (Suzh…Phase 1

T cell injection targeting FLT3 chimeric antigen receptor (T cell injection targeting FLT3 chimeric antigen receptor)

FLT3-positive Relapsed/Refractory Acute Myeloid Leukemia · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Active
CGTLimited DatastaleUniversity of PennsylvaniaPhase 1

T cells modified with RNA anti -cMET CAR (T cells modified with RNA anti -cMET CAR)

Malignant Melanoma; Breast Cancer · Malignant Melanoma

#MalignantMelanoma#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Discontinued
AntibodyLimited DatastaleTriumvira Immunologics, Inc.Phase 2

pembrolizumab (Keytruda, TAC01-HER2 plus pembrolizumab)

HER2 Positive Gastric Cancer; Metastatic HER2 Positive Gastroesophageal Junction Cancer · HER2

#HER2#Antibody#Phase2#monoclonal-antibody#HER2PositiveGastricCancer+2
Trials 1Status Discontinued
AntibodyLimited DatastaleRochePhase 1

TACE combined with sintilimab and bevacizumab (TACE combined with sintilimab and bevacizumab)

Hepatocellular Carcinoma Non-resectable · Hepatocellular Carcinoma Non-resectable

#HepatocellularCarcinomaNon-resec#Antibody#Phase1#monoclonal-antibody#Roche
Trials 1Status Active
AntibodyLimited DatastaleSecond Affiliated Hospital of G…Phase 2

TACE combined with sorafenib and tislelizumab (TACE combined with sorafenib and tislelizumab)

Hepatocellular Carcinoma Non-resectable · Hepatocellular Carcinoma Non-resectable

#HepatocellularCarcinomaNon-resec#Antibody#Phase2#monoclonal-antibody#Second
Trials 1Status Active
AntibodyLimited DatastaleSun Yat-sen UniversityPhase 2

atezolizumab (Tecentriq, TACE-HACI, plus atezolizumab-bevacizumab)

Hepatocellular Carcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#Antibody#Phase2#monoclonal-antibody#Sun
Trials 1Status Recruiting
AntibodyLimited DatastalePresage BiosciencesPhase 1

TAK-981 + Avelumab (TAK-981 + Avelumab)

Head and Neck Cancer · Head and Neck Cancer

#HeadandNeckCancer#Antibody#Phase1#monoclonal-antibody#Presage
Trials 1Status Active
AntibodyLimited DatastalePresage BiosciencesPhase 1

TAK-981 + Cetuximab (TAK-981 + Cetuximab)

Head and Neck Cancer · Head and Neck Cancer

#HeadandNeckCancer#Antibody#Phase1#monoclonal-antibody#Presage
Trials 1Status Active
AntibodyLimited DatastaleRochePhase 2

TAS-102+bevacizumab+local treatment (TAS-102+bevacizumab+local treatment)

Metastatic Colorectal Cancer (CRC) · Metastatic Colorectal Cancer (CRC)

#MetastaticColorectalCancerCRC#Antibody#Phase2#monoclonal-antibody#Roche
Trials 1Status Recruiting
AntibodyLimited DatastaleAsan Medical CenterApproved

TDM-based infliximab intravenous therapy (TDM-based infliximab intravenous therapy)

Crohn Disease; Infliximab · Crohn Disease

#CrohnDisease#Antibody#Approved#monoclonal-antibody#Infliximab+1
Trials 1Status Recruiting
CGTLimited DatastaleM.D. Anderson Cancer CenterPhase 1

TGFBR-2 KO CD70 CAR NK (TGFBR-2 KO CD70 CAR NK)

Clear Cell Carcinoma; Phase 1 · Clear Cell Carcinoma

#ClearCellCarcinoma#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 1Status Recruiting

87 / 103 pages

← PreviousNext →